LENZ Therapeutics (LENZ) Other Accumulated Expenses (2020 - 2023)

LENZ Therapeutics (LENZ) has 4 years of Other Accumulated Expenses data on file, last reported at $143000.0 in Q4 2023.

• On a quarterly basis, Other Accumulated Expenses fell 89.44% year-over-year to $143000.0 in Q4 2023; TTM through Dec 2023 was $143000.0, a 89.44% decrease from a year earlier, with the FY2023 full-year figure at $143000.0, down 89.44% from the prior year.
• Other Accumulated Expenses for Q4 2023 stood at $143000.0, down from $221000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for LENZ reached as high as $4.9 million in Q1 2023 and fell as low as $71000.0 in Q4 2020.
• Historically, Other Accumulated Expenses has averaged $1.0 million across 4 years, with a median of $420500.0 in 2021.
• On a YoY basis, Other Accumulated Expenses climbed as much as 1611.17% in 2023 and fell as far as 89.44% in 2023.
• Year by year, Other Accumulated Expenses stood at $71000.0 in 2020, then soared by 411.27% to $363000.0 in 2021, then jumped by 273.0% to $1.4 million in 2022, then slumped by 89.44% to $143000.0 in 2023.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $143000.0 in Q4 2023, $221000.0 in Q3 2023, and $3.1 million in Q2 2023.